A reproducible and quantitative imaging biomarker to standardize the evaluation of changes in bone scans is an unmet need for prostate cancer patients with skeletal metastasis. Here we have performed a series of analytical validation studies to evaluate the performance of the automated Bone Scan Index (BSI) as an imaging biomarker in patients with metastatic prostate cancer (mPCa).